Multiple Sclerosis
Conditions
Keywords
Ocrevus, B cell, T cell, cytokines
Brief summary
The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. The goal of the study is to understand the role of regulatory B cell, T cell and other factors in mediating the therapeutic effects of Ocrevus.
Interventions
DRUGOcrelizumab
Description Needed
Sponsors
University of Michigan
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Patients with MS either with relapsing or primary progressive course; who are newly starting on ocrelizumab (Ocrevus) at the time of enrollment OR Healthy controls who do not have a significant medical conditions such as cancer, chronic infection, or autoimmune disease, have not taken steroids in the past 2 months, and who are not on an immune suppressant medication. * Ability to give informed consent * Willing to have blood drawn as scheduled in the protocol * Willing and able to complete all procedures and evaluations related to the study
Exclusion criteria
* Medical or psychiatric conditions that may affect the patient's ability to give informed consent * Has received an experimental drug within 30 days of enrollment * Concomitant other disease modifying medications (such as Rebif, Betaseron, Avonex, Copaxone, Gilenya, Tecfidera, Aubagio, Mayzent, Mavenclad, Alemtuzumab, methotrexate, azathioprine, Novantrone, cyclophosphamide, cyclosporine, Tysabri, Rituxan, Ocrevus, etc.) * Has any contraindication to high-dose immunotherapy, including pregnancy, trying to become pregnant, or breast feeding during the study * Active hepatitis B virus infection * History of life-threatening infusion reaction to Rituxan or Ocrevus * Chronic infection or any severe acute infection within 3 months prior to screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in frequency of regulatory B cells | From baseline to 24 months | Percentage B cells measured by flow cytometry. Compare Ocrevus treatment to baseline and to healthy controls |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in frequency of T cell subtypes | From baseline to 24 months | Percentage of T cells measured by flow cytometry. Compare Ocrevus treatment to baseline and to healthy controls |
Countries
United States
Outcome results
None listed